Search

Displaying results 841 - 850 of 10000 in total
  1. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Chinese hamster ovary cell line [FDA Label]. … In particular, while human thrombin products are made from pooled human source plasma, recombinant thrombin is a human coagulation protein produced via recombinant DNA technology from a genetically modified

  2. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

  3. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

  4. Drug

    Aspartic acid

    go.drugbank.com/drugs/DB00128
    ApprovedInvestigationalNutraceutical

    One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.

    Mixtures: Olimel 7.6% E, Olimel 4.4% E
  5. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … According to 2017 American Association for the Study of Liver Diseases (AASLD), 60mg of daclatasvir is recommended with 400mg [DB08934] for genotype 1a/b patients with or without cirrhosis as second-line

  6. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

  7. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. … activity in the uterus and breast.

  8. Drug

    Triprolidine

    go.drugbank.com/drugs/DB00427
    Approved

    First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.

    Mixtures: COUGH-EN LINCTUS, COUGH-EN LINCTUSSynonyms: (E)-2-[3-(1-pyrrolidinyl)-1-p-toluenepropenyl]pyridine, trans-1-(2-pyridyl)-3-pyrrolidino-1-p-tolylprop-1-ene
  9. Drug

    Benzoyl peroxide

    go.drugbank.com/drugs/DB09096
    ApprovedInvestigational

    [A234059,A234064,A234069] Benzoyl peroxide, in combination with erythromycin, was granted FDA approval on 26 October 1984.[L33264] … Benzoyl peroxide is a commonly used drug in topical treatments for acne.

    Mixtures: Clean and Clear Advantage 2-in-1 Acne and Mark Eraser KitProducts: NO + ACNE CREMA PARA EL ACNE NON GRAS ®, All-IN-one
  10. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.